We asked nearly two dozen doctors to tell us about their professional lives: Their inspirations, their best advice, and their ...

The BMS-Pfizer Alliance announced a new direct-to-patient option for purchasing discounted apixaban (Eliquis) beginning in ...

We expect Incyte Corporation INCY to surpass expectations when it reports second-quarter 2025 earnings on July 29, before the ...

Fetal exposure to inflammation has long been identified as a risk factor for a range of harmful conditions, but new research ...

Experts representing multiple societies and institutions across 14 countries have published guidance for computed tomography ...

Program builds pipeline of patients and caregivers trained to be directly involved in research WASHINGTON, July 22, 2025 /PRNewswire/ -- LU ...

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and ...

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previ ...

ImmunityBio sees bullish momentum from ASCO data and UK approval for ANKTIVA, despite FDA and cash risks. Check out why IBRX ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancers ...